Among the available agents, VDRAs were proven effective in inhibiting PTH secretion by acting directly on the parathyroid gland.(50, 51) The goal of VDRA therapy is therefore to minimize the bone consequences of hyperparathyroidism and to ultimately reduce fracture risk. Here, PTH is linked to hyperparathyroidism.